• Recorded Webinar and Slides - Taking Global Action Toward Improved Care, Quality of Life, and Empowerment for Older People with HIV - A Webinar
   
  
• Glasgow: The Glasgow Manifesto International Coalition of Older People with HIV (iCOPe HIV)
   
  
• IAS Recorded Feb 7 webinar - Growing older with HIV in the Treat-All Era
   
  
• CROI: Summary from CROI 2023 for HIV and liver disease What is new in viral hepatitis coinfection? Is fatty liver disease a growing concern? New insights from CROI 2023. - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/16/23)
   
  
• CROI: COVID at CROI 2023 - (03/27/23)
   
  
• CROI: Psychiatric Symptoms In PLHIV: Prevalences, Interactions And Consequences - here are slides in Themed Discussion & poster. - (03/27/23)
   
  
• CROI: THE SCIENCE OF AGING: LESSONS FOR HIV AT THE INTERFACE OF COMMONALITY AND HETEROGENEITY, George Kuchel - (03/27/23)
   
  
• CROI: COMPLICATIONS Oral Abstract Session-06 at CROI 2023 - (03/27/23)
   
  
• CROI: Weight Gain: Does what Goes Up Come Down ? Themed Discussion - (03/27/23)
   
  
• CROI: Weight Gain: Does what Goes Up Come Down ? Themed Discussion - (03/27/23)
   
  
• CROI: Anal Cancer Prevention & Microbiome Biomarkers - (03/27/23)
   
  
• CROI: HIV-1 Host Reservoir Reactivation after a
  CCR5Δ32/32 Allogeneic Hematopoietic Stem Cell Transplant - (03/27/23)
   
  
• CROI: Paxlovid Reduced by 98% Hospitalization: COVID-19 HOSPITALIZATION RISK AFTER SARS-CoV-2 VACCINATION AND OUTPATIENT TREATMENT - (03/27/23)
   
  
• CROI: Psychiatric Symptoms In PLHIV: Prevalences, Interactions And Consequences - here are slides in Themed Discussion & poster. - (03/27/23)
   
  
• CROI: VIRAL AND HOST MEDIATORS OF PERSISTENT LOW-LEVEL VIREMIA (NSV) - (03/27/23)
   
  
• CROI: ADVANCES IN HIV CURE at CROI 2023, John Mellors - (03/27/23)
   
  
• CROI: Predictors of Post-Switch Viremia in Patients on Injectable Cabotegravir/Rilpivirine - (03/27/23)
   
  
• CROI: LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV - (03/27/23)
   
  
• CROI: LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV - (03/277/23)
   
  
• CROI: SOLAR 12-MONTH RESULTS: RANDOMIZED SWITCH TRIAL OF CAB+RPV LA VS ORAL B/FTC/TAF - (03/27/23)
   
  
More HIV Articles...
 

• HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
   
  
• CROI: BULEVIRTIDE +/- PEG-IFN IN HIV/HBV/HDV CO-INFECTED PATIENTS IN REAL-LIFE SETTINGS - (03/22/23)
   
  
• Low Performance of Hepatitis Delta Virus Testing Among 2 National Cohorts of Chronic Hepatitis B Patients in the United States - (01/24/23)
   
  
• Hepatitis D (Delta) Course Review: Conference Reports: USA/Global Prevalence, Mortality-HCC Impact, PWIDs, Treatment, Screening, Patient Support - (01/13/23)
   
  
More Hep D Articles...
 


---


 
Aging & Perinatally HIV Infected
 

• CROI: Sleep disturbances are associated with cognitive function in women living with HIV - (03/01/23)
   
  
• CROI: Comparison of Telomere Length Changes Over 48 Weeks in SALSA Study: DTG/3TC vs CAR - (02/21/23)
   
  
• Aging & Disproportionate disability in people with HIV - (02/20/23)
   
  
More Aging & HIV Articles...
 


---


 
Mpox
 

• A case of mpox reinfection - (03/22/23)
   
  
• CROI: EFFECTIVENESS OF SMALLPOX VACCINATION TO PREVENT MPOX IN MILITARY PERSONNEL - (03/02/23)
   
  
More Monkeypox Articles...
 

• CROI: CLINICAL AND LABORATORY OUTCOMES OF HEPATITIS C TREATMENT IN AN ACUTE HIV COHORT - (03/22/23)
   
  
• CROI: Risk factors for liver fibrosis progression in HIV: a multi-center longitudinal study - (03/16/23)
   
  
• CROI: Sofosbuvir/Velpatasvir Pharmacokinetics in Pregnant Women with Hepatitis C Virus - (03/14/23)
   
  
• Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States - (03/14/23)
   
  
• A National Hepatitis C Elimination Program in the United States - A Historic Opportunity - (03/14/23)
   
  
• Biden $5 Bill HCV Ask for HCV Elimination in New Budget Submitted to Congress - (03/14/23)
   
  
• CROI: Intervention efficacy on COVID-19 testing and vaccination in people who inject drugs - Mark Mascolini (03/02/23)
   
  
• CROI: PRIMARY HCV INCIDENCE AMONG MSM USING PREP AND MSM WITH HIV IN NEW YORK CITY 2012-2022 - (03/01/23)
   
  
• CROI: TARGET3D: glecaprevir-pibrentasvir for four weeks among people with recent HCV infection - (02/23/23)
   
  
• Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection - (02/19/23)
   
  
• Global- Only 2% & 13% of HCV & HBV Infections Treated - (02/15/23)
   
  
• Homeless HCV Treatment-Holistic Care - Patient Centered Required - (02/09/23)
   
  
• Recommendations for Implementing Hepatitis C Virus Care in Homeless Shelters: The Stakeholder Perspective - (02/09/23)
   
  
More Hep C Articles...
 

• External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection - (03/16/23)
   
  
• CROI: PREDICTORS OF HEPATITIS B TREATMENT RESPONSE IN PEOPLE WITH HIV/HBV COINFECTION - (02/20/23)
   
  
• New Approaches to Chronic Hepatitis B - (01/06/23)
   
  
• HBV Panel: New Screening/Treatment Recommendations - It Is Time for a Simplified Approach to Hepatitis B Elimination, Editorial too. - (01/06/23)
   
  
• AASLD: Low level of hepatitis B viremia increases the risk of hepatocellular carcinoma in patients with untreated compensated cirrhosis - (11/28/22)
   
  
• AASLD: Profile of HBV DNA integration in the natural history of chronic hepatitis B - (11/28/22)
   
  
• AASLD: Comparable outcomes between immune-tolerant and active phases in non-cirrhotic chronic hepatitis B: a meta-analysis - (11/28/22)
   
  
More Hep B Articles...
 


---


 
Fatty Liver, NAFLD, NASH
 

• INTERCEPT ANNOUNCES FDA ADVISORY COMMITTEE MEETING DATE FOR OBETICHOLIC ACID AS A TREATMENT FOR PRE-CIRRHOTIC LIVER FIBROSIS DUE TO NASH PRESS RELEASE - (03/14/23)
   
  
• CROI: PREVALENCE AND FACTORS ASSOCIATED WITH NAFLD IN PEOPLE WITH HIV - (02/21/23)
   
  
• CROI: CONTROLLED ATTENUATION PARAMETER IS A VISCERAL ADIPOSITY MARKER IN HIV-RELATED NAFLD - (02/21/23)
   
  
• CROI: SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE - (02/21/23)
   
  
• CROI: NAFLD AND ITS COMBINATION WITH NASH PREDICT DM DEVELOPMENT IN PEOPLE WITH HIV - (02/21/23)
   
  
• CROI: LIVER STEATOSIS AND FIBROSIS IN WOMEN WITH HIV BY INTEGRASE INHIBITOR USE - (02/21/23)
   
  
More Fatty Liver Articles...
 

List not necessarily listed here in order of date being held.